Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of immunotherapy that is often applied in the treatment of patients with hematologic malignancies such as acute myeloid leukemia (AML). 1 AML has a poor prognosis that can be significantly improved when the allogeneic immune system induces a potent graft versus leukemia (GvL)
immune response.
Tumor immune responses are considered T cell mediated and enhancing T cell responses, for example with checkpoint inhibitors, has significantly improved clinical outcome in a number of solid tumors and lymphoma's. 2 In allogeneic HSCT, transplantation of T cell depleted grafts was associated with high leukemia relapse rates 3 and this and other studies established the importance of T cells in GvL responses. 1, 4, 5 Similarly, killer immunoglobulin receptor (KIR) mismatched NK cells that are alloreactive against AML blasts significantly impacted allogeneic HSCT outcomes. 6 Emerging evidence suggests that B cells and antibodies are also involved in anti-tumor immune responses. In colorectal tumors B cells are one of the dominant infiltrating lymphocyte populations and their interaction with follicular T cells was associated with survival. 7 In ovarium carcinoma and other solid tumors, tumor B cell infiltration was the single most predictive marker of response to neo-adjuvant chemotherapy. 8, 9 In allogeneic HSCT recipients, serum analysis of patients with potent GvL responses demonstrated the appearance of antibodies against tumor-associated antigens. 10, 11 However, proof that donor-derived antibodies contribute to the anti-tumor immune response in allogeneic HSCT recipients is lacking.
Here we investigated the functionality of antibodies produced by donor-derived B cells in GvL responses. From allogeneic HSCT recipients who remained in complete remission despite high-risk AML we established clonal B cell lines producing antibodies that were highly specific for AML. A significant number of these antibodies, which were all donor-derived, recognize the U5 snRNP200 complex, a component of the spliceosome that is expressed in the nucleus of normal cells but is exposed on the surface of AML cells. U5 snRNP200 complex-specific antibodies are directly cytotoxic for AML blasts in the absence of effector cells or complement suggesting that these antibodies contribute to the anti-tumor response in HSCT recipients. 184 had an early relapse AML M2 after a sib-RIST but obtained complete remission after reinduction chemotherapy with high-dose cytarabine followed by donor-lymphocyte infusion.
Materials and methods

Patients
All patients experienced GvHD, but none of the patients had clinically active GvHD at the moment of B cell isolation (Table 1) . Post allogeneic HSCT multiple myeloma patients and healthy individuals were included as controls. Freshly isolated AML blasts were obtained from blood or bone marrow of patients with newly diagnosed AML. B-non Hodgkin's lymphoma cells were obtained as waste material from diagnostic punctures and biopsies. Endothelial cells were isolated from umbilical cords (human umbilical vein endothelial cells or HUVECS).
Healthy bone marrow was acquired from the sternum of patients undergoing thoracotomy for cardiac surgery. Healthy PBMCs were isolated from buffy coats from blood donations (Sanquin, Amsterdam). CD3-IgA+ B cells on a FACSAria (Becton Dickinson) and transduced with a BCL-6 and Bcl-xL construct as described previously. 12 Transduced B cells were expanded with IL-21 on CD40L-expressing fibroblasts and supernatants containing antibodies were screened for binding to target cells by flow cytometric analysis.
Isolation of B cells and generation of AML-specific B cell clones
Target confirmation: snRNP200 ELISA HEK 293T cells were transfected with an expression vector containing the full-length open reading frame of snRNP200 with a N-terminal FLAG tag or a H77 E1E2 FLAG tagged construct (control). Cells were harvested and lysed with 0,5% Triton X114 lysis buffer. This lysate was cleared and protein concentration was assessed. AML specific antibodies, control antibodies or commercially available snRNP200 specific antibodies (Bethyl) were coated on a goat anti-human IgG (Jackson) or anti-rabbit pre-coated ELISA plate. The lysate was added at a concentration of 5 μg/ml for capturing. After extensive washing, captured snRNP200-flag was detected with a monoclonal mouse anti-flag HRP antibody (Sigma, clone M2).
Cell death assays
For imaging, Calcein AM labeled THP-1 cells (10 nM) were incubated with AML-specific antibodies (10 μg/ml) for 15 minutes and transferred to a 96 well flat bottom SpectraPlate (PerkinElmer) where cytotox Red (Essen Bioscience) was added (0.5 μM). Cells were imaged using a Leica DMi8 (Leica Microsystems) inverted wide-field microscope, with GFP and Texas
Red filter cubes, 40x oil objective, at 37°C in an atmosphere containing 5% CO 2 . Time-lapse movies from three independent experiments were taken at 2-minute intervals for at least 3h using Adaptive Focus Control. Images were processed with the LAS X software (Leica Microsystems). Cell death and adhesion quantification was done with 1000-2000 (after 3h) and 150-300 (15min and 1h) different cells per antibody, respectively. To measure apoptosis THP-1 cells were stained with 40nM of DiOC6 (3,3-dihexyloxacabocyanine iodide; Molecular Probes / Invitrogen) for 20 minutes at 37°C after which propidium iodide (PI) was added. To block apoptosis THP-1 cells were pre-incubated with 100 μM Z-VAD-FMK or 10 μM Q-VD-OPh (R&D) and incubated with 1-10 μg/ml AML or control antibodies, DMSO vehicle control or Diclofenac for 24 hours. 14, 15 Cytocholasin D was used at 10 μg/ml, with 20 minutes incubation on ice (Sigma).
In vivo AML xenograft mouse model
SCID mice (8 mice per group) were inoculated with THP-1 subcutaneously. At an average tumor size of 106 mm 3 , 3 weeks after inoculation, treatment with control antibody (AT1002) or recombinant U5 snRNP200 antibodies rAT1337 and rAT1331 was started. Treatment consisted of biweekly intraperitoneal dosages at a concentration of 10mg/kg of antibody for 3 consecutive weeks. Treatment tolerability was assessed by body weight measurements and frequent observations for clinical signs of treatment-related side effects. Tumors were measured twice weekly in two dimensions using calipers and tumor volume was calculated as tumor volume (mm 3 ) = (width 2 (mm) x length (mm))/2. Treatment outcome was based on tumor growth delay (TGD) by performing a time to endpoint (TTE) analysis of individual mice. The endpoint was set as at a tumor size of 350mm 3 , to prevent censored cases. Tumors of the two best and worst responders per treatment group were harvested at day 25 and formalin fixed and embedded in paraffin. Tissue sections were stained with Hematoxylin and Eosin (H&E). Slide pictures were digitalized and tumor and necrotic areas were measured using Philips Digital Pathology Solution version 2.3.1.1.
Statistics
All statistical analyses were done using GraphPad PRISM 6.0f. The confirmation snRNP200 ELISA was repeated in three separate experiments. Significant difference was determined with multiple t tests of a Two-way ANOVA analysis. Screening of healthy controls, MM and AML patients in a U5 snRNP200 complex ELISA was repeated in two separate experiments.
Differences were determined with multiple comparisons in a One-way ANOVA. The same was done for the H&E slides where tumor surface area and area of necrosis were measured and compared. Tumor growth delay in days to the defined end point of 350mm 3 was analyzed using survival curve statistics. As a proportional hazard to reach the endpoint was assumed, a log-rank (Mantel-cox) test was performed.
Results
Identification of AML specific antibodies
We selected three patients with high-risk AML that achieved ongoing, durable (at the time of writing of this paper >7 years) remission following allogeneic HSCT (Table 1, patients 58, 59 and 101). To test whether these patients had generated AML-specific antibodies, we searched for AML-binding antibody-producing B cells. Peripheral blood B cells were transduced with BCL-xL and BCL-6 and cultured as described previously. 12 We deposited 20 or 40 immortalized B cells per well of 96 or 384 well microtiter plates to generate mini-cultures and tested supernatants of these cultures for antibodies binding to AML cell lines using flow cytometry ( Figure 1A ). As all 3 patients had been diagnosed with (myelo)monocytic AML we selected the THP-1, Molm13 and MonoMac6 cell lines, that are morphologically and phenotypically similar to (myelo)monocytic AML, for these screening assays. Mini cultures of which the supernatant specifically bound the AML cell lines but not control cells were selected, single cells of these cultures were deposited in wells of microtiter plates and following expansion their supernatants were screened for binding against AML cell lines ( Figure 1A ). Using this approach we identified 16 monoclonal B cell lines, producing antibodies that bound to THP-1, Molm13, Monomac6 and freshly isolated AML blasts of newly diagnosed patients ( Figure 1B and Table   2 ) but not to non-AML cell lines or hematopoietic (including PBMC, bone marrow, tonsil and cord blood) or non-hematopoietic cells of healthy individuals ( Figure 1C and data not shown).
AML-binding clones were of the IgG1 or IgG3 isotype, and the variable heavy (VH) and light (VL) chain regions of most of the antibodies showed somatic hypermutations, indicative of in vivo antigen exposure of these B cells (Table 3 ). All AML-specific antibodies detected were of donor-origin as determined with micro-chimerism analysis of genomic polymorphisms by profiling of short tandem repeat (STR) DNA loci of B cell clones (data not shown). Antibodies in the supernatant of one of the mini-cultures (11C9; 40 cells / well) binding to the AML cell line THP-1 (top panels). B cells from this mini-culture were plated into 1 cell/well solutions and supernatants again screened for antibodies binding to THP-1 (lower panels). Positive control: HLA-DR; negative control: in-house generated, influenza-specific antibody AT1002. 13 Recombinant produced 11C9-22C11 was named AT1223. 
A:
Immunoblotting of THP-1 immunoprecipitates with AT1223, AT1331 and AT1002 with rabbit-snRNP200, -PRPF8, -EFTUD2 and mouse-GAPDH specific antibodies. B: Jurkat and THP-1 cells were stained with a commercially available rabbit-anti-PRPF8 (Abcam), -snRNP200 (Bethyl Labs) and -EFTUD2 (Abcam) antibodies on the membrane (left panels) and intracellular (right panels). Polyclonal rabbit anti-hepatitis core antigen (HBcAg) was used as negative control (grey filled histograms).
A-B:
Depicted is one representative experiment of at least three independent experiments. See also Table 2 . Seven AML-specific antibodies recognize the U5 snRNP200 complex, as tested in ELISA. Depicted are means of 3 independent experiments and standard deviations; asterisk: p<0.003. SnRNP200: commercially available rabbit anti-snRNP200; snRNP200-flag: flag-tagged snRNP200 lysate; flag-tagged hepatitis C specific protein (H77/E1/ E2-flag) was used as a negative control. AT1002: influenza specific antibody; HBcAg: polyclonal rabbit anti-hepatitis core antigen. 
Target identification of AML-specific antibodies: U5 snRNP200 complex
We selected three antibodies and generated recombinant forms for further analysis: AT1223 (IgG3), AT1337 (IgG3) and AT1331 (IgG1). Immunoprecipitation (IP) of cell membrane and total lysates of THP-1 cells by AT1223 and AT1331 yielded specific bands at ~250 and ~120 kDa. LC MS/MS analysis of the ~250kDa AT1331 band identified the U5 small nuclear ribonucleoprotein helicase snRNP200 (Brr2, HELIC2) and its close relative helicase ASCC3 (HELIC1), complexed with the U5 spliceosome components Prpf8 (Prp8) and EFTUD2 (snRNP116) in the ~120kDa band as the major hits. Western blot analysis confirmed the U5 snRNP200 complex as the target of these antibodies (Figure 2A ). The U5 snRNP200 complex is a large multiprotein component of the spliceosome indispensable for pre-mRNA splicing and located in both nucleus and cytoplasm. 16 We confirmed the intracellular localization of the U5 snRNP200 complex in the Jurkat T cell leukemia cell line and in THP-1 cells with commercially available U5 snRNP200-, Prpf8-and EFTUD2-specific antibodies. Contrary to Jurkat cells, THP-1 cells expressed the U5 snRNP200 complex also on the plasma membrane ( Figure 2B ).
In addition to AT1223 and AT1331, the antibodies AT1337, AT1225, AT1333, AT1335 and AT1508 specifically recognize the U5 snRNP200 complex, as determined by ELISA ( Figure 2C ).
These antibodies are derived from all three patients screened, suggesting it is a commonly recognized antigen in AML patients. Screening B cells of 2 other AML patients with robust, lasting anti-tumor immunity after allogeneic HSCT (Table 1 ; patients 102 and 184) by ELISA identified U5 snRNP200 complex-specific B cell clones in one of them (patient 102; Figure 2D) that was confirmed by FACS (not shown). Thus, U5 snRNP200 complex-specific B cells were found in 4 out of 5 transplanted AML patients. In contrast, screening of 3 multiple myeloma patients who remained in remission after allogeneic HSCT did not yield U5 snRNP200 complex binding clones ( Figure 2D ). In the same ELISA screen, one out of 5 healthy individuals showed U5 snRNP200 complex positive mini bulk cultures ( Figure 2D ) but binding of these clones could not be confirmed with FACS (not shown). Thus, none of the healthy individuals screened mounted significant B cell responses against U5 snRNP200 complexes ( Figure 2D ). Since in contrast to AML blasts multiple myeloma cells do not express cell surface U5 snRNP200 complex proteins, our data indicate the U5 snRNP200 complex to be immunogenic upon exposure on cell surfaces of tumor cells, explaining why antibodies specific for this complex are found only in AML patients ( Figure 2D ). Immunoprecipitation of the mouse AML cell line WEHI-3B with AT1331 confirmed the U5 snRNP200 complex as the target antigen. Mouse and human snRNP200 are 99.7% homologous, confirming that the antibodies recognize a highly conserved epitope ( Figure 2E ). FACS analysis of these cells showed that the U5 snRNP200 complex antibodies bind these cells, indicating that the mechanism of extracellular expression of these proteins is conserved across species. THP-1 cells were incubated with AML-specific antibodies for 4 hours at 37°C, after which cell death was measured using a standard bead controlled assay. Numbers on the x-axis denote each specific AML-specific antibody; asterisk indicate antibodies that are specific for the U5 snRNP200 complex. Co: heat-inactivated medium control. 
U5 snRNP200 antibodies induce non-apoptotic cell death in vitro
Incubation of THP-1 cells with the AML antibodies showed that some of the AML-specific antibodies prevented in vitro outgrowth of THP-1 cells while other AML-specific antibodies or non-AML specific antibodies did not ( Figure 3A and 3B) . Cells did not become resistant to killing; when THP-1 cells that survived the first incubation with AT1337 and AT1331 were again incubated with the U5 snRNP200 antibodies, outgrowth of cells was again prevented ( Figure   3A , right panel). Screening the killing capacity of all AML specific antibodies revealed that all U5 snRNP200 complex-recognizing AML-specific antibodies killed THP-1 cells in vitro ( Figure  3B ). Two non-snRNP200 binding AML specific antibodies, AT1322 and AT1336, also induced death of more than 40% of the THP-1 cells ( Figure 3B) ; the specificities of these antibodies remain to be determined. U5 snRNP200 complex-specific antibodies killed target cells in a dose-dependent manner ( Figure 3C ). Importantly, expansion of primary AML cells (obtained from patients BL-038 and BL-063) was blocked when cultured in the presence of AT1331 or AT1337 ( Figure 3D ). Many pathways of non-apoptotic cell death have been described, 17 but none of these pathways have been as clearly defined as apoptotic cell death. A distinctive feature that we observed is the rapid adherence and flattening out of target cells in the presence of U5 snRNP200 complex antibodies. Thus, upon incubation with AT1337, cells become adherent, and then lose membrane integrity and die ( Figure 4D , Figure 4E and Supplemental Video 1). AT1331 induced less adherence, but also with this antibody, most adherent cells died ( Figure 4D and 4E). Of note, AT1331 is an IgG1 antibody, while AT1337 is an IgG3 antibody. As IgG3 antibodies bind to FcRs with higher affinity than IgG1 antibodies, 18 the superior cytotoxicity of AT1337 could be related to its IgG3 format. To test this, we produced AT1331 recombinant in an IgG3 format, but this did not improve cytotoxicity (data not shown). In fact, when AT1337 was produced as a recombinant IgG3 antibody (rAT1337), the antibody was significantly less cytotoxic compared to the natural (B cell derived) sAT1337 antibody ( Figure 4E ). Recombinant rAT1337 did only briefly reduce target cell motility ( Figure 4D ), and the extent of adherence induced by the U5 snRNP200 complex antibodies seemed to relate to the amount of target cell death induced. For these experiments the IgG3 antibody sAT1412 was used as a control antibody. This antibody binds THP-1 cells but despite its IgG3 format does not induce target cell adhesion or death.
When target cells were incubated with the actin polymerization inhibitor cytochalasin D, cell death was prevented, while antibody binding to the cells was unaffected ( Figure 4F ). Together these data suggest that patient derived, U5 snRNP200 complex specific antibodies induced death of target cells via a non-apoptotic, Fc dependent process that bring forth tracking forces that lead to loss of target cell membrane integrity.
U5 snRNP200 antibodies delay tumor growth and can induce tumor necrosis in vivo
Given the specificity and the functional activities of the snRNP200 specific antibodies we hypothesized that these antibodies might have contributed to the tumor free status of the patients from whom the antibodies were derived. To test this hypothesis we examined the capacity of these U5 snRNP200 complex binding antibodies to affect tumor growth in vivo.
Three weeks after subcutaneous injection of THP-1 cells into 24 mice we treated the animals biweekly with either of two anti snRNP200-specific antibodies or a control antibody at a dose of 10mg/kg. For these experiments large amounts of antibody could only be produced in a recombinant, thus less cytotoxic format. Nevertheless, we found that treatment with rAT1331
and rAT1337 resulted in a significant tumor growth delay compared to treatment with isotype control ( Figure 5A ). When mice were sacrificed, 25 days after the start of treatment and 8 days after the last antibody injection, tumor sizes were no longer different between groups but the amount of viable tumor tissue was significantly lower in the rAT1331 treated group ( Figure 5B and Figure 5C ). These data demonstrate that U5 snRNP200 complex-specific antibodies affects growth of THP-1 cells in vivo. Interestingly, no obvious adverse effects were noted in the mice treated with the U5 snRNP200 antibodies, despite that the antibodies react with mouse U5 snRNP200 indicating that these antibodies do not act on normal cells and could therefore be safe for therapeutic application. Of each tumor, the area of necrosis was calculated as percentage of the total surface. While total tumor sizes did no longer differ between groups after 25 days, tumors from rAT1331 treated mice had significantly more necrotic tissue.
Discussion
Our data indicate that cell surface exposure of U5 snRNP200 complexes is tumor-specific and that engagement of this complex by antibodies can induce non-apoptotic cell death. The cell surface exposed U5 snRNP200 complex as a target for tumor antibodies was unexpected, because this complex is normally expressed within the cell. Although U5 snRNP200 cell surface expression on tumor cells has not been described before, some examples are known of ribonucleoproteins that are exposed on the cell membrane. 19 Moreover, components of spliceosomes have been identified as auto-immune targets in systemic lupus erythematosus (SLE) and mixed connective tissue disease. [20] [21] [22] Mutations in spliceosome components have been described in many cancers, 23 including AML and MDS. [24] [25] [26] High-turnover cancers actually depend on the spliceosome to expand. 27 U5 snRNP200 complex membrane expression, specifically observed for human and mouse AML blasts and not healthy cells, may reflect spliceosomal stress in leukemic blasts. However, the mechanism by which the U5 snRNP200 complex is exposed on the membrane of the tumor cells remains unclear.
Cytotoxic or killer antibodies that induce non-apoptotic programmed cell death have been described before. Antibodies directed against Lewis(y) and Lewis(b) that are expressed on a range of tumor types kill tumor cells in a non-apoptotic way. 28 Anti-NeuGcGM3 antibodies kill non-small cell lung cancer cells expressing this antigen by inducing membrane pores. 29 The CD20 antibody obinutuzumab that is now tested in the clinic kills leukemia and lymphoma cells via a non-apoptotic mechanism that depends on actin reorganization. 30, 31 A very recent report describes the antibody TAG-A1 that selectively kills undifferentiated human embryonic stem cells (hESC) via excess reactive oxygen species (ROS) production. 32 Similar to the U5 snRNP200 complex antibodies that we identified, these antibodies induce cell death in an autonomous way via a non-apoptotic mechanism, characterized by cell swelling, that cannot be blocked by pan-caspase inhibitors. Killer antibodies induce actin reorganization resulting in the formation of pores that lead to the rapid disintegration of target cells. This process has been named 'oncosis', 32,33 a non-apoptotic programmed death pathway that similar to pyroptosis, necroptosis and others represents an area of active research. 34 Some of the U5 snRNP200 complex antibodies harbored a significant number of somatic hypermutations in the heavy and light chains, implying antigen exposure induced affinity maturation in vivo. Our data suggest that leukemia-specific cytotoxic antibodies generated in transplanted AML patients contribute to the tumor free status of these patients. This is in line with the observation that a patient with U5 snRNP200 complex expressing AML who relapsed after allogeneic HSCT had not developed U5 snRNP200 complex specific antibodies (data not shown). Moreover, in a previous study we described a patient who simultaneously developed an AML-specific antibody response and a potent GvL response; after depletion of B cells with rituximab (for steroid-refractory GvHD) AML relapsed in this patient suggesting the AML antibodies were functional in this case. 35 Immunological checkpoint blockade studies have established that tumor-specific cytotoxic T lymphocytes specifically recognizing neo-antigens are important effectors in anti-tumor immunity. Neo-antigens arise due to mutations in malignant cells and the immunogenicity of cancers is amongst others correlated with their mutational status, with highly mutated cancers such as melanoma and non-small cell lung carcinoma more susceptible to immunotherapy, particularly with checkpoint inhibitors. 2, 36 AML is characterized by a low mutational status 37 and may therefore be less immunogenic for T cells and less sensitive to checkpoint inhibition than highly mutated cancers. Our study demonstrates that also tumors with relatively few mutations can be immunogenic in the setting of allogeneic HSCT, resulting in a tumor-specific antibody response.
Our data raise the possibility that antibodies obtained from patients who achieved long-term remission of their cancer have therapeutic utility. U5 snRNP200 complex antibodies may potentiate the effect of conventional chemotherapeutic regimens, as has been demonstrated for the CD20 antibodies rituximab and obinutuzumab in B cell non-Hodgkin lymphoma. In addition such antibodies may have a vaccinal effect by inducing long-term anti-tumor T cells responses as reported recently. 38, 39 Moreover, the U5 snRNP200 complex has potential as a target for chimeric antigen receptor (CAR) T cells using the antibody as the CAR. Finally, our findings demonstrate that screening the antibody repertoire of cancer patients enables the discovery of novel tumor-associated antigens that can be targeted by therapeutic or diagnostic antibodies or tumor-specific vaccines.
